Index
Click on each headline to read the full post.
Ischemic Stroke
2021 - 13% increase, 2022 - 20% increase (vs. 2017-2020 avg.)
IS in babies & children: Constant rise in events during 2021, peak was March 2022 with 5.7 times monthly avg.
Vaccinated vs. Unvaccinated - explicit increase in IS cases in Vaccinated during second booster rollout
Cardiac Arrest
x2.5 cardiac arrest Deaths vs. expected, age 40-50
2022 spikes in cardiac arrest events only occurred in vaccinated
Extraordinary correlation between cardiac arrest deaths in 40-50 age group, all-cause mortality peaks, and vaccination timeline
Cancer of Unknown Primary cause (CUP)
x3 increase in 3 years
Basic statistical data regarding 31 types of cancer
Guillain-Barré syndrome
Rise in case numbers detected in certain age groups
Pulmonary Embolism (PE)
15.6% rise in Pulmonary Embolism (PE) rate in Israel 2021-2022
All-cause mortality
Israel's Central Bureau of Statistics’ all-cause mortality data raises serious doubts regarding vaccine efficacy & safety
Age-stratified relative monthly mortality
Explicit excess mortality in young people
Excess mortality in the elderly population
Lockdowns and collateral damage
Israel vs. Sweden mortality
Infant Mortality
Analysis of the Ministry Of Health’s weekly epidemiological reports
Infant Mortality Rate: 2021 - 5% rise, 2022 - 10% rise
Alleged trend reversal vs. earlier years
Sarcoidosis
Sarcoidosis is a rare disease involving abnormal collections of inflammatory cells that form lumps known as granulomata
In 2021 the rates of both genders were above average (compared to 2016-2020 baseline) : Males presented an 11% rise, Females 10%
2022 presented an even stronger rise above average, higher than any other year, for both genders: Males 35% rise, Females 16%
Several case reports were already published in journals on sarcoidosis following mRNA vaccines
Israeli MOH: Zero Covid19 deaths of healthy under age 50
Translation and discussion of the MOH’s statement
About us
“Israel has become the world’s lab” - Pfizer CEO
Who we are and what we do
What we found
Limitations
Please subscribe to receive future updates, and share…